Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy

British Journal of Clinical Pharmacology

Volumn 79, Issue 5, 2015, Pages 847-859

  Lexchin, Joel ^a  

^a York University   (Canada)

Author keywords

Health Canada; new active substances; post market safety warnings; priority review; standard review

Indexed keywords

ABACAVIR; ABATACEPT; ABIRATERONE; ACAMPROSATE; ADALIMUMAB; ADEFOVIR; AGALSIDASE ALFA; ALATROFLOXACIN; ALEFACEPT; ALEMTUZUMAB; ALISKIREN; ALITRETINOIN; ALMOTRIPTAN; AMBRISENTAN; AMINOLEVULINIC ACID; AMLEXANOX; AMPRENAVIR; ANIDULAFUNGIN; APIXABAN; APREPITANT; ARGATROBAN; ARIPIPRAZOLE; ATAZANAVIR; ATOMOXETINE; AXITINIB; AZACITIDINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT STEM CELL FACTOR; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ARTICLE; CANADA; DRUG APPROVAL; DRUG EFFICACY; DRUG PACKAGING; DRUG SAFETY; HUMAN; KAPLAN MEIER METHOD; POLICY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; DRUG RECALL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; LEGISLATION AND JURISPRUDENCE; STANDARDS; STATISTICS AND NUMERICAL DATA;

CANADA; DATABASES, FACTUAL; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84928350430     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12552     Document Type: Article

References (19)

1. Health Canada: Health Products and Food Branch. Access to Therapeutic Products: The Regulatory Process in Canada. Ottawa: Health Canada: Health Products and Food Branch, 2006.
2. Health Canada. Preparation of Human New Drug Submissions. Ottawa: Health Canada, 1991. Available at http://publications.gc.ca/collections/collection-2013/sc-hc/H42-2-38-1991-eng.pdf (last accessed 11 June 2014).
3. Health Canada: Health Products and Food Branch. Guidance for industry: priority review of drug submissions. 2009.
4. Health Canada. Notice of Compliance with Conditions (NOC/c). Ottawa: Health Canada, 2002.
5. Health Products and Food Branch. Guidance document: notice of compliance with conditions (NOC/c). 2011.
6. Lexchin J,. Notice of compliance with conditions: a policy in limbo. Healthc Policy 2007; 2: 114-122.
7. Lexchin J,. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med 2012; 172: 1680-1681.
8. Law M,. The characteristics and fulfillment of conditional prescription drug approvals in Canada. Health Policy 2014; 116: 154-161.
9. Patented Medicine Prices Review Board. Compendium of policies, guidelines and procedures-reissued June 2014. 2014. Available at http://www.pmprb-cepmb.gc.ca/view.asp?ccid=492 (last accessed 21 June 2014).
10. Lexchin J,. International comparison of assessments of drug innovation. Health Policy 2012; 105: 221-225.
11. Downing N, Aminawung J, Shah N, Krumholz H, Ross J,. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 2014; 311: 368-377.
12. U.S. Food and Drug Administration. Fast track, Breaktrhough Therapy, Accelerated Approval and Priority Review. Silver Spring, MD: U.S. Department of Health & Human Services, 2014. Available at http://www.fda.gov/ForPatients/Approvals/Fast/default.htm (last accessed 21 June 2014).
13. Berlin RJ,. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization. Am J Public Health 2009; 99: 1693-1698.
14. Richey E, Lyons E, Nebeker J, Shankaran V, McKoy M, Luu T, Nonzee N, Trifilio S, Sartor O, Benson AB III, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL,. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009; 27: 4398-4405.
15. European Commission. Commission regulation (EC) no. 507/2006. Official J Eur Union 2006; L: 92/6-928.
16. European Medicines Agency. Guideline on Procedures for Granting of A Marketing Authorisation under Exceptional Circumstances, Persuant to Article 14 (8) of Regulation (EC) NO 726/2004. London: European Medicines Agency, 2005.
17. Arnardottir A, Hasijer-Ruskamp F, Straus S, Eichler H-G, de Graeff P, Mol P,. Additional safety risk to exceptionally approved drugs in Europe. Br J Clin Pharmacol 2011; 72: 490-499.
18. Boon W, Moors E, Meijer A, Schellekens H,. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther 2010; 88: 848-853.
19. Marketed Health Products Directorate. How Adverse Reaction Information on Health Products Is Used. Ottawa: Marketed Health Products Directorate, 2004.